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We have previously provided the first genetic evidence that Angiotensin converting enzyme 2 
(ACE2) is the critical receptor for SARS-CoV and that ACE2 protects the lung from injury, 
providing a molecular explanation for the severe lung failure and death due to SARS-CoV 
infections. ACE2 has now also been identified as a key receptor for SARS-CoV-2 infections and 
it has been proposed that inhibiting this interaction might be used in treating patients with COVID-
19. However, it is not known whether human recombinant soluble ACE2 (hrsACE2) blocks growth 
of SARS-CoV-2. Here we show that clinical grade hrsACE2 reduced SARS-CoV-2 recovery from 
Vero cells by a factor of 1,000-5,000. An equivalent mouse rsACE2 had no effect. We also show 
that SARS-CoV-2 can directly infect engineered human blood vessel organoids and human kidney 
organoids, which can be inhibited by hrsACE2. These data demonstrate that hrsACE2 can 






Outbreaks of emerging infectious diseases continue to challenge human health. The reported 
incidence of emerging and re-emerging zoonotic disease is increasing in many parts of the world. 
The Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) first emerged 17 years ago 
(Drosten et al., 2003). In December of 2019, a novel coronavirus (SARS-CoV-2) crossed species 
barriers to infect humans (Gorbalenya et al., 2020) and was effectively transmitted from person to 
person, leading to a pneumonia outbreak first reported in Wuhan, China (Guan et al., 2020; Jiang 
et al., 2020; Zhou et al., 2020b). This virus causes coronavirus disease-19 (COVID-19) with 
influenza like symptoms ranging from mild disease to severe lung injury and multi-organ failure, 
eventually leading to death, especially in older patients with other co-morbidities. The WHO has 
declared that COVID-19 is a public health emergency of pandemic proportions 
(https://www.who.int/). The SARS-CoV-2 pandemic is not only an enormous burden to public 
health but has already markedly affected civil societies and the global economy.  
 
SARS-CoV-2 shares multiple similarities with SARS-CoV (Andersen et al., 2020; Lu et al., 2020; 
Zhu et al., 2020). Phylogenetic analysis of SARS-CoV-2 demonstrated that this virus belongs to 
lineage B of the betacoronavirus genus (Chan et al., 2020; Letko et al., 2020). The receptor binding 
domain (RBD) of SARS-CoV-2 is similar to the SARS-CoV RBD, suggesting a possible common 
host cell receptor. ACE2 was identified as the functional SARS-CoV receptor in vitro and, by our 
group, in vivo (Imai et al., 2005; Kuba et al., 2005). Overexpression of human ACE2 enhanced 
disease severity in mice infected with SARS-CoV, demonstrating that ACE2-dependent viral entry 
into cells is a critical step (Yang et al., 2007). We reported that injecting SARS-CoV spike into 
mice decreased ACE2 expression levels, thereby worsening lung injury (Imai et al., 2005; Kuba 
et al., 2005). Thus, ACE2 serves both as the entry receptor of SARS-CoV and to protect the lung 
from injury (Zhang et al., 2020).  
 
Three recent cryo-EM studies demonstrated that SARS-CoV-2 spike protein directly binds to 
ACE2 and that the SARS-CoV-2 spike protein recognizes human ACE2 with even higher binding 
affinity than Spike from SARS-CoV (Walls et al., 2020; Wan et al., 2020; Wrapp et al., 2020). 
Recently, it has been  demonstrated in cell culture that soluble ACE2 fused to Ig (Wrapp et al., 
2020) or a nonspecific protease inhibitor called camostat mesylate (Hoffmann et al., 2020), can 
inhibit infections with a Pseudovirus bearing the S protein of SARS-CoV-2. High doses 
(100g/ml) of camostat mesylate were also shown to partially reduce SARS-CoV-2 growth, as 
expected from previous studies with other viruses (Hoffmann et al., 2020).  
 
In a normal adult human lung, ACE2 is expressed primarily in alveolar epithelial type II cells, 
which can serve as a viral reservoir (Zhao et al., 2020). These cells produce surfactant which 
reduces surface tension, thus preventing alveoli from collapsing, and hence are critical to the gas 
exchange function of the lung (Dobbs, 1989). Injury to these cells could explain the severe lung 
injury observed in COVID-19 patients. We and others have also shown that ACE2 is expressed in 
multiple extra-pulmonary tissues including heart, kidneys, blood vessels, and intestine (Crackower 
et al., 2002; Danilczyk and Penninger, 2006; Ding et al., 2004; Gu et al., 2005; Hamming et al., 
2004; Zhang et al., 2020). The ACE2 tissue distribution in these organs may explain the multi-
organ dysfunction observed in patients (Guan et al., 2020; Huang et al., 2020). Here, we report 
that clinical-grade human recombinant soluble ACE2 (hrsACE2), which has already been tested 
in phase 1 and phase 2 clinical trials (Haschke et al., 2013, Khan et al., 2017), can reduce viral 
growth in Vero E6 cells by a factor of 1,000-5,000. Moreover, we show that human blood vessel 
organoids and kidney organoids can be readily infected, which can be significantly inhibited by 




Isolation of a SARS-CoV-2  
To study potential therapeutic interventions for COVID-19, in early February 2020 we isolated the 
SARS-CoV-2 from a nasopharyngeal sample of a patient in Sweden with confirmed COVID-19. 
After successful culture on Vero E6 cells, the isolated virus was sequenced by Next-Generation 
Sequencing (Genbank accession number MT093571).  Electron microscopy showed the prototypic 
coronal shape of viral particles of our SARS-CoV-2 isolate (Figure 1A). Phylogenetic analysis 
showed the virus belongs to the clad A3 (Figure 1B).   
 
hrsACE-2 can inhibit SARS-CoV-2 infection in a dose dependent manner 
hrsACE2 has already undergone clinical phase 1 and phase 2 testing (Khan et al., 2017) and is 
being considered for treatment of COVID-19 (Zhang et al., 2020). Since ACE2 is the SARS-CoV-
2 receptor, we wanted to provide direct evidence that clinical-grade hrsACE2 can indeed interfere 
with SARS-CoV-2 infections. To this end, we infected Vero-E6 cells (cells used for SARS-CoV-
2 isolation) with different numbers of SARS-CoV-2: 103 plaque forming units (PFUs; MOI 0.02), 
105 PFUs (MOI 2) and 106 PFUs (MOI 20). Viral RNA as a marker for replication was purified 
from cells and assayed by qRT-PCR (Figure 2A). Infection of cells in the presence of hrsACE2 
during 1 hr, followed by washing and incubation without hrsACE2 significantly inhibited SARS-
CoV-2 infections of Vero-E6 15 hours post infection (Figure 2A). 
 
These data demonstrate that hrsACE2 inhibits the attachment of the virus to the cells. Importantly, 
as expected from a neutralizing agent, this inhibition was dependent on the initial quantity of the 
virus in the inoculum and the dose of hrsACE2 (Figure 2A), establishing dose-dependency. In 
contrast to hsrACE-2, the equivalent mouse recombinant soluble ACE2 (mrsACE2), produced in 
the same way as hrsACE2, did not inhibit the infection (Figure 2B). Finally, we performed 
experiments where cells were infected with SARS-CoV-2 in the presence of hrsACE2 or mrsACE2 
for 15 hr, to capture any newly produced virus particles during the 15hr that could infect 
neighbouring cells. Again, we observed significantly reduced virus infections in the presence of 
hrsACE2 (Figure 2C), but not mrsACE2 (Figure 2D). Of note, addition of human or mouse 
rsACE2 was not toxic to the Vero-E6 cells, monitored for 15 hours (data not shown). These data 
show that hrsACE2 significantly reduces SARS-CoV-2 infections in vitro.  
 
hrsACE-2 inhibits SARS-CoV-2 infections of human capillary organoids  
A primary site of SARS-CoV-2 infection appears to be the lung, which may be a source for viral 
spread to other tissues such as the kidney and intestine, where virus has been found (stool and 
urine) (Ling et al., 2020; Wang et al., 2020; Young et al., 2020). Moreover, viremia is established 
during the course of the disease, although viral RNA in blood is only infrequently observed (Wang 
et al., 2020). However, the virus has a size of 80-100nm indicating that viremic SARS-CoV-2 must 
first infect blood vessels prior to local tissue infections. To test this hypothesis, we established 
human capillary organoids from induced pluripotent stem cells (iPSCs) (Figure 3A) and infected 
them with our SARS-CoV-2 isolate. Of note, these organoids closely resemble human capillaries 
with a lumen, CD31+ endothelial lining, PDGFR+ pericyte coverage, as well as formation of a 
basal membrane (Wimmer et al., 2019). The capillary organoids were analysed by qRT-PCR for 
the presence of viral RNA at day 3 and 6 after primary SARS-CoV-2 exposure. Importantly, 
following infection, we could detect viral RNA in the blood vessel organoids with viral RNA 
increasing from day 3 to day 6 post infection (Figure 3B), indicating active replication of SARS-
CoV-2.  
 
Supernatant of infected organoids collected at day 6 post-infection could efficiently infect Vero 
E6 cells (Figure 3C), showing that the infected capillary organoids produced progeny virus. 
Importantly, addition of hrsACE2 markedly reduced SARS-CoV-2 infections of the engineered 
human blood vessels (Figure 3D). Of note, addition of human or mouse rsACE2 was not toxic to 
human blood-vessels, monitored for 3 days (data not shown). These data show that human 
capillary organoids can be infected with SARS-CoV-2 and this infection can be significantly 
inhibited by hrsACE2.   
 
 
hrsACE-2 can inhibit SARS-CoV-2 infections of human kidney organoids  
We and others have previously shown that ACE2 is strongly expressed in kidney tubules 
(Danilczyk and Penninger, 2006). Moreover, it has been reported that SARS-CoV-2 can be found 
in the urine (Ling et al., 2020). To test whether SARS-CoV2 can directly infect human tubular 
kidney cells, we generated kidney organoids from human embryonic stem cells into 3D suspension 
culture, adapting our own protocol (Garreta et al., 2019). Importantly, kidney differentiation 
organoids demonstrated prominent tubular-like structures as detected by Lotus Tetraglobus Lectin 
(LTL) as a marker of proximal tubular epithelial cells (Figure 4A). Tubular-like cells also 
expressed the solute carrier SCL3A1 (Figure S1A) together with SCL27A2 and SCL5A12. 
Furthermore, LTL positive (LTL+) cell fractions from organoids expressed markers of proximal 
tubular identity (Figure S1B and S1C). Single cell profiling of kidney organoids showed the 
presence of cells expressing ACE2 in the proximal tubule and podocyte II cell clusters that express 
key marker genes of proximal tubular cells (SLC3A1, SLC27A2) and podocytes (PODXL, 
NPHS1, NPHS2), respectively (Figure S2). Thus, kidney organoids contain cell clusters that 
express ACE2 in a similar fashion to that observed in the native tissue (Lin et al. 2020).   
 
Infections of kidney organoids were monitored 6 days after SARS-CoV-2 infection and assayed 
for the presence of viral RNA using q-RT-PCR. Progeny virus was determined as above using re-
infections of Vero E6 cells. As expected from cells and tissues that express ACE2, SARS-CoV-2 
replicated in kidney organoids (Figure 4B). Supernatant of infected kidney organoids collected at 
day 6 post-infection could efficiently infect Vero E6 cells (Figure 4C), showing that the engineered 
kidney organoids produced infectious progeny virus. Importantly, addition of hrsACE2 
significantly reduced SARS-CoV-2 infections of the human kidney organoids in a dose dependent 
manner (Figure 4D). Of note, addition of human or mouse rsACE2 was not toxic to the kidney, 
monitored for 3 days (data not shown). These data indicate that besides blood vessels, engineered 
human kidney organoids can also be infected with SARS-CoV-2 and this infection can be inhibited 
by hrsACE2.   
 
Discussion 
ACE2 took centre stage in the COVID-19 outbreak as the key receptor for the spike glycoprotein 
of SARS-CoV-2, as demonstrated in multiple structural and biochemical interaction studies 
(Wrapp et al., 2020; Zhou et al., 2020b). Moreover, multiple drug development projects, including 
development of vaccines are focusing on the ACE2-SARS-CoV-2 Spike interactions. We initially 
identified mammalian ACE2 when we realized that flies carry two orthologues of ACE 
(Angiotensin-converting enzyme). Our first ace2 mutant mice then demonstrated that ACE2 is a 
negative regulator of the renin-angiotensin system (RAS) and genetically controls cardiovascular 
function and damage of multiple organs such as the lung, liver, and kidney (Clarke and Turner, 
2012; Crackower et al., 2002). ACE2 catalytically removes the last amino acid of angiotensin II, 
thereby counterbalancing ACE and Ang II actions and generating “beneficial” downstream 
peptides such as Ang1-7. ACE2 also catalytically acts on other peptides such as in the Apelin/APJ 
system (Clarke and Turner, 2012). 
 
Importantly, we reported that ACE2 protects from lung injury, based on its catalytic domain, and 
that ACE2 is the critical in vivo SARS-CoV spike glycoprotein receptor (Imai et al., 2005; Kuba 
et al., 2005). Initially two receptors had been identified for SARS-CoV in cell lines, namely ACE2 
(Li et al., 2003) and the lectin L-SIGN (Jeffers et al., 2004). The severity of SARS could be 
partially explained by SARS-CoV Spike protein binding to ACE2 at a molecular interaction site 
that does not interfere with its catalytic activity (Li et al., 2005), which then leads to endocytosis 
of the virus and loss of ACE2 (Kuba et al. 2005), establishing a vicious circle of viral infection 
and local loss of lung injury protection. This led to the initiation of a drug development program 
– the development of soluble recombinant human ACE2, a drug that has undergone phase 1 testing 
in healthy volunteers and phase 2 testing in some patients with acute respiratory distress syndrome 
(ARDS) (Haschke et al., 2013; Khan et al., 2017; Treml et al., 2010). Our data now show that this 
clinical-grade human ACE2 molecule - but not mouse soluble ACE2 - can significantly inhibit 
SARS-CoV-2 infections and reduce viral load by a factor of 1,000-5,000. However, as observed 
in antibody neutralizing experiments of many viruses, the inhibition is not complete, though clearly 
dose-dependent. This may be due to the fact that there might be other co-receptors/auxiliary 
proteins or even other mechanisms by which viruses can enter cells, as had been initially proposed 
for SARS (Jeffers et al., 2004; Qi et al., 2020). Such a second receptor has been also suggested 
based on clinical data: SARS transmissibility was very low possibly due to the low level expression 
of ACE2 in the upper respiratory tract (Bertram et al., 2012; Hamming et al., 2004). 
Transmissibility of SARS-CoV-2 is much greater than that of SARS-CoV, suggesting that SARS-
CoV-2 might use a co-receptor and/or other factors which allow infection of ACE2 expressing 
cells in the upper respiratory tract (Lukassen et al., 2020). Most importantly, our results 
demonstrate that hrsACE2 significantly blocks SARS-CoV-2 infections, providing a rationale that 
soluble ACE2 might not only protect from lung injury but also block the SARS-CoV-2 from 
entering target cells.  
 
Pathology due to SARS, MERS, and now COVID-19 is not limited to the lung; damage can occur 
in multiple organs (Gu et al., 2005; Wu and McGoogan, 2020; Yeung et al., 2016). ACE2 is 
expressed in various tissues including the heart, kidney tubules, the luminal surface of the small 
intestine, and blood vessels (Crackower et al., 2002; Danilczyk and Penninger, 2006; Ding et al., 
2004; Gu et al., 2005; Hamming et al., 2004; Zhang et al., 2020), suggesting that SARS-CoV-2 
could also infect these tissues. We now show that blood vessels as well as kidney organoids can 
be readily be infected by SARS-CoV-2. SARS-CoV-2 must enter the blood stream to infect other 
tissues. However, the size of the infectious viral particles is about 80-100nm (Wrapp et al., 2020). 
Thus, unless there is already tissue damage, the virus must enter vascular endothelial cells to 
migrate into the organs. Our data in engineered human capillary organoids now suggest that SARS-
CoV-2 could directly infect blood vessel cells. Infected blood vessel organoids also shed progeny 
viruses. Importantly, hrsACE2 markedly inhibited SARS-CoV-2 infections of the vascular 
organoids.  
 
ACE2 is strongly expressed in kidney tubules, controlling a local RAS circuit (Clarke and Turner, 
2012; Hashimoto et al., 2012). As an infection model, we therefore engineered human kidneys 
organoids from stem cells differentiated to contain tubular networks (Garreta et al., 2019). We now 
show that SARS-CoV-2 can infect such human kidney organoids, resulting in infectious viral 
progeny, inhibited by hrsACE2. Clinically, SARS-CoV-2 has been found in the urine (Ling et al., 
2020) and many patients with COVID-19 present with cardiovascular and renal dysfunctions 
(Huang et al., 2020; Shi et al., 2020; Yang et al., 2020; Zhou et al., 2020a). Whether direct viral 
infection of the vasculature and kidneys directly contribute to the observed multi-organ damage in 
COVID-19 patients needs to be established. Given the fact that cardiac cells express high levels of 
ACE2, and heart alterations were the first phenotype observed in our ace2 mutant mice (Crackower 
et al. 2002), it will be important to expand on our studies to heart and in particular lung organoids 
to better understand the multi-organ dysfunction in patients with COVID-19.  
 
Our study has limitations. The design of our studies focused on the early stages of infection, 
demonstrating that hrsACE2 can block early entry of SARS-CoV-2 infections in host cells. As 
such, we cannot make any predictions with respect to the effect of hrsACE2 in later stages of the 
disease process. Secondly, we did not study lung organoids, and the lung is the major target organ 
for COVID-19. Finally, the RAS system represents a complex network of pathways which are 
influenced by external processes which are not simulated in our model systems. To address these 
issues, further studies are needed to illuminate the effect of hrsACE2 at later stages of infection in 
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Main figure legends 
Figure 1. SARS-CoV-2 Sweden virus analyses.  
A) Electron microscopy image of a viral particle of the Swedish SARS-CoV-2 isolate. B) 
Phylogenetic tree mapping the Swedish SARS-CoV-2 to clade A3.  
 
Figure 2. Human recombinant soluble ACE2 (hrsACE2) blocks SARS-CoV-2 infections.   
A) Different concentrations of human recombinant ACE2 (hrsACE2) were mixed with SARS-
CoV-2 for 30 minutes and then added to the culture medium of Vero-E6 cells. Cells were washed 
after 1 hour post-infection (h.p.i.) and incubated with fresh medium. Cell were recovered 15 hours 
post-infection and viral RNA was assayed by qRT-PCR. Data are represented as mean ± SD.** 
P<0.01; *** P<0.001. B) Murine recombinant soluble ACE2 (mrsACE2) did not significantly 
affect SARS-CoV-2 infections of Vero-E6 cells, highlighting the specificity of hrsACE2 in 
blocking SARS-CoV-2 entry. mrsACE2 was mixed with SARS-CoV-2 for 30 minutes and then 
added to the culture medium of Vero E6 cells. Cells were washed after 1 h.p.i and incubated with 
fresh medium. Cell were recovered 15 hours post-infection and viral RNA was assayed by qRT-
PCR. Data are represented as mean ± SD C) Effect of hrsACE2 treatment on progeny virus. Vero 
E6 cells were infected with the indicated M.O.I. of SARS-CoV-2, (the inoculum was not removed). 
Cells were recovered 15 h.p.i. and viral RNA was assayed by qRT-PCR. Inhibition of the progeny 
virus by hsrACE2 resulted in significantly reduced virus infections Data are represented as mean 
± SD (Student t test: *P<0.05; ** P<0.01). D) Murine recombinant soluble ACE2 (mrsACE2) did 
not significantly affect SARS-CoV-2 infections of Vero-E6 cells, highlighting the specificity of 
hsrACE2 in blocking SARS-CoV-2 entry. Vero-E6 cells were infected with the indicated M.O.I. 
of SARS-CoV-2 treated with murine recombinant soluble ACE2. Cells were harvested at 15 h.p.i 
and viral RNA was assayed by qRT-PCR. 
 
Figure 3. SARS-CoV-2 infections of blood vessels organoids.  
A) Representative images of vascular capillary organoids using light microscopy (magnifications 
x 10) (upper panels) and immunostaining of blood vessel organoids using anti-CD31 to detect 
endothelial cells and anti-PDGFR to detect pericytes. DAPI (blue) was used to visualize nuclei. 
Scale bars, 500µm and 50µm (inset). B) Recovery of viral RNA from blood vessel organoids at 
day 3 and 6 post-infection (dpi) with SARS-CoV-2, demonstrating that the virus can infect the 
vascular organoids. Data are represented as mean ± SD. C) Determination of progeny virus. 
Supernatants of SARS-CoV-2 infected blood vessel organoids were collected 6 dpi and then used 
to infect Vero E6 cells. After 48 hours, Vero E6 cells were washed and viral RNA assessed by 
qRT-PCR. The data show that infected blood vessel organoids can produce progeny SARS-CoV-
2 viruses, depending on the initial level of infection. Data are represented as mean ± SD. D) Effect 
of hrsACE2 on SARS-CoV-2 infections of blood vessel organoids. Organoids were infected with 
a mix of 106 infectious viral particles and hrsACE2 for 1 hour. 3 days post-infection, levels of viral 
RNA were assessed by qRT-PCR. hrsACE2 significantly decreased the level of SARS-CoV-2 
infections in the vascular organoids Data are represented as mean ± SD (Student t test: ** P<0.01).  
 
Figure 4. SARS-CoV-2 infections of human kidney organoids.  
A) Representative images of a kidney organoid at day 20 of differentiation visualized using light 
microscopy (top left inset; Scale bar 100 m) and confocal microscopy. Confocal microscopy 
images show tubular-like structures labelled with Lotus Tetraglobus Lectin (LTL, in green) and 
podocyte-like cells showing positive staining for Nephrin (in turquoise). Laminin (in red) was used 
as a basement membrane marker. DAPI labels nuclei. A magnified view of the boxed region shows 
a detail of tubular structures. Scale bars 250 and 100m, respectively. B) Recovery of viral RNA 
in the kidney organoids at day 6 post-infection (dpi) with SARS-CoV-2. Data are represented as 
mean ± SD. C) Determination of progeny virus. Supernatants of SARS-CoV-2 infected kidney 
organoids were collected 6 dpi and then used to infect Vero E6 cells. After 48 hours, Vero E6 cells 
were washed and viral RNA assessed by qRT-PCR. The data show that infected kidney organoids 
can produce progeny SARS-CoV-2 viruses, depending on the initial level of infection. Data are 
represented as mean ± SD. D) Effect of hrsACE2 on SARS-CoV-2 infections kidney organoids. 
Organoids were infected with a mix of 106 infectious viral particles and hrsACE2 for 1 hour. 3 
days post-infection, levels of viral RNA were assessed by qRT-PCR. hrsACE2 significantly 
decreased the level of SARS-CoV-2 infections in the kidney organoids Data are represented as 
mean ± SD. (Student t test: * P<0.05).  
Supplementary figure legends 
Figure S1. Human kidney organoids as a surrogate of human proximal tubule cell culture 
model, related to Figure 4  
A) Left image corresponds to a kidney organoid at day 20 of differentiation visualized using light 
microscopy.  Scale bar 100 m. Confocal microscopy images of tubular-like structures labelled 
with Lotus Tetraglobus Lectin (LTL, in green) and the proximal tubular cell marker SCL3A1 (in 
red). DAPI labels nuclei. A magnified view of the boxed region shows a detail of the tubular 
structures. Scale bars 250 and 50m, respectively. B) Expression changes of SLC3A1, SLC5A12 
and SLC27A2 of bulk samples at day 20 of organoid differentiation. C) Left image corresponds 
to LTL+ cells visualized using light microscopy. Scale bar 100 m. Confocal microscopy images 
of LTL+ cells labelled with Lotus Tetraglobus Lectin (LTL, in green) and the proximal tubular cell 
markers NaK ATPase (NaK, in red) and the solute carrier SGLT2 (in red). DAPI was used to 
visualize nuclei. Scale bars 100m. 
Figure S2. Single cell RNA-seq analysis of kidney organoids reveals ACE2 expression in 
proximal tubule cells, related to figure 4  
A) UMAP plot displaying the results after unbiased clustering. Subpopulations of renal 
endothelial-like, mesenchymal, proliferating, podocyte and tubule cells were identified. B) 
Expression of ACE2 projected in the UMAP reduction. C) Expression of different cellular 
markers: SLC3A1, SLC27A2 (Proximal Tubule); PODXL, NPHS1, NPHS2 (Podocyte); CLDN4, 
MAL (Loop of Henle) and CD93 (Renal Endothelial-like cells). 
STAR METHOD  
KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Fluorescein labeled Lotus Tetragonolobus (LTL) Vector Labs  FL-1321 
RRID:AB_2336559 
Anti-SLC3A1 polyclonal antibody   Merck HPA038360-100U 
RRID:AB_2675975
  
Anti-SGLT2    Abcam ab37296 
RRID:AB_777895 
Anti-LAMININ      Merck L9393 
RRID:AB_477163 
Human Nephrin Affinity Purified Polyclonal Ab 
antibody     
R&D Systems AF4269  
RRID:AB_2154851 




Bacterial and Virus Strains  
SARS-CoV-2, GENBANK: MT093571  Isolated from patient N/A 
Biological Samples 
Chemicals, Peptides, and Recombinant Proteins 
CHIR99021 Merck SML1046; CAS: 
252917-06-9 
Recombinant human FGF9  PeproTech 100-23 
Heparin Merck H3149; CAS: 9041-
08-1 
Activin A Vitro 338-AC-050 
Paraformaldehyde solution 4% in PBS Santa Cruz sc-281692 
1% Triton X-100 Merck T8787 
Glutaraldehyde Sigma-Aldrich G7776 
srhACE2 Apeiron N/A 
Trizol ThermoFisher 15596018 
Recombinant Human VEGF165 Peprotech 100-20 
Human FGF-2 Miltenyi Biotech 130-093-841 
Critical Commercial Assays 
streptavidin/biotin blocking kit Vector Labs SP-2002 
CellTiter-Glo® Luminescent cell viability assay Promega G7570 
Direct-zol RNA MiniPrep kit Zymo Reasearch R2051 
Chromium Single Cell 3’ Library & Gel Bead Kit 
V3 
10X Genomics (USA) PN-1000075 
NSQ 500/550 Hi Output KT v2.5 (75 CYS) Illumina (San Diego, 
CA 92122 USA) 
20024906 






Kidney Organoid scRNA-seq This paper GEO: GSEXXXX 
Experimental Models: Cell Lines 
ES[4] Human Embryonic Stem Cell line  
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Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact, Joseph Penniger (josef.penninger@ubc.ca). 
 
Materials Availability 
All unique organoids generated in this study are available from the Lead Contact with a completed 
Materials Transfer Agreement. 
 
Data and Code Availability 
Raw sequencing data for the single cell kidney organoid reported in this paper were deposited in 
Gene Gene Expression Omnibus. (GEO) under the accession number GEO: GSEXXXXX. 
 
Scripts reproducing the single cell kidney analysis are deposited in: 
https://github.com/jpromeror/SC_KidneyOrganoid_ACE2 
 




SARS-CoV-2 was isolated on Vero-E6 cells, from a nasopharyngeal sample of a patient in 
Sweden. Virus was titered using a plaque assay as previously described (Becker et al., 2008) with 
fixation of cells 72 hours post infection. The SARS-CoV-2 isolate was sequenced by Next-
Generation Sequencing (Genbank accession number MT093571). For electron microscopy, viral 
stocks were inactivated using 35% Glutaraldehyde.  
 
Preparation of soluble recombinant human and murine ACE2 
Clinical-grade soluble recombinant human ACE2 (amino acids 1-740) was produced by Polymun 
Scientific (contract manufacturer) from CHO cells according to Good Manufacturing Practice 
guidelines and formulated as a physiologic aqueous solution. The equivalent domain of murine 
ACE2 was similarly overexpressed in CHO cells under serum free conditions and purified by 
sequentially performing a capture step on DEAE-Sepharose, ammonium sulfate precipitation, 
purification via a HIC-Phenyl Sepharose column, followed by purification via a Superdex 200 gel 
filtration column. The purity of the murine protein was determined via HPLC, concentrations were 
determined with 280nm photometric measurements. 
 
Cells and human capillary organoids 
Vero-E6 cells (ATCC) were grown in Dulbecco’s Modified Eagle’s Medium (DMEM, 
Thermofisher) supplemented with 1% Non-Essential Amino-Acid (Thermofisher), 10mM Hepes 
(Thermofisher) and 10% FBS at 37°C, 5% CO2. Blood vessels organoids were engineered from 
human iPS cells and immunostained as previously described (Wimmer et al., 2019a).  
 
Kidney organoid differentiation 
Human embryonic stem cells were grown on vitronectin coated plates (1001-015, Life 
Technologies) and incubated with 0.5mM EDTA (Merck) at 37oC for 3 minutes for 
disaggregation. 100,000 cells/well were plated on a 24 multi-well plate coated with 5μl/ml 
vitronectin and further incubated with supplemented Essential 8 Basal medium at 37oC overnight. 
The day after (day 0), cells were treated for 3 subsequent days in Advanced RPMI 1640 basal 
medium (ThermoFisher) supplemented with 8μM CHIR (Merck) and 1% Penicillin-Streptomycin 
and 1% of GlutaMAX TM (ThermoFisher). The medium was changed every day. From day 3 to 
4, media were changed to Advanced RPMI supplemented with 200ng/ml FGF9 (Peprotech), 
1μg/ml heparin (Merck) and 10ng/ml activin A (Vitro). On day 4, cultures were rinsed twice with 
PBS, and resuspended in Advanced RPMI supplemented with 5μM CHIR, 200ng/ml FGF9 and 
1μg/ml Heparin. Cellular suspensions were seeded in V-shape 96 multi-well plate at a final 
concentration of 100,000 cells/well and centrifugated at 2000 rpm for 3 minutes. The resulting 
spheroids were incubated during 1h at 37ºC. Culture media was replaced by Advanced RPMI 
supplemented with 200ng/ml FGF9 and 1μg/ml Heparin for 7 additional days, the media was 
changed every second day. From day 11 to 16, developing organoids were incubated only in the 
presence of Advanced RPMI, the media was every second day. 
 
Phylogenetic analysis 
To generate a phylogenetic tree, we created a genomic epidemiology map of different SARS-CoV-
2 isolates using NextStrain tools (https://nextstrain.org/) (Hadfield et al., 2018). The sequences of 
the different isolates were obtained from GISAID (https://www.gisaid.org/) (Elbe and Buckland-
Merrett, 2017). Screenshots is used under a CC-BY-4.0 license. 
 
Treatments of Vero E6 cells with human rsACE2 and murine rsACE2 
Vero E6 cells were seeded in 48-well plates (5.104 cells per well) (Sarstedt) in DMEM containing 
10% FBS. 24 hours post-seeding, hrsACE2 or mrsACE2 were mixed with different concentration 
of virus (1:1) in a final volume of 100µl per well in DMEM (0% FBS) at 37°C. After 30 minutes, 
Vero-E6 were infected either with mixes containing hrsACE2/SARS-CoV-2 and 
mrsACE2/SARS-CoV-2 for 1 hour followed by washing or for 15 hours without washing, cells 
were washed 3 times with PBS and 500µl of new complete medium supplemented with hrsACE2 
or mrsACE2 were added. 15 hours post-infection, supernatants were removed, cells were washed 
3 times with PBS and then lysed using Trizol™ (Thermofisher) before analysis by qRT-PCR for 
viral RNA detection. 
 
SARS-CoV-2 infections of kidney and blood vessel organoids 
Kidney organoids were infected with 103 or 105 SARS-CoV-2 infectious particles in advanced 
RPMI medium (Thermofisher). Blood vessels organoids were infected with 102, 104, or 106 SARS-
CoV-2 infectious particles in StemPro complete media containing 15% FBS (Gibco 
cat.10500064), 100ng/ml of VEGF-A (Peprotech cat. no. 100-20) and 100ng/ml of FGF-2 
(Milteny Biotech cat. no. 130-093-841) as previously described (12) in a volume of 50µl per well 
of a 96-well ultra-low attachment plate for 1 hour. One hour post-infection, organoids were washed 
3 times with PBS and kept in 100µl of corresponding medium for 3 to 6 days. On day 3 post-
infection, organoids were washed 3 times with PBS before being lysed with Trizol™ 
(Thermofisher). At day 6 post-infection, supernatants were recovered and organoids washed 3 
times with PBS before to lysis with Trizol™ (Thermofisher). Samples were then analysed for the 
presence of viral RNA by qRT-PCR. 100µl of each supernatant were used to infect Vero E6 in 48-
well plate plates. Cells were recovered 48 hours post-infection, pooled (5 blood-vessels organoids/ 
condition, 3 kidney organoids/condition), and the level of infection was determined by viral RNA 
detection using qRT-PCR.  
 
Treatment of organoids with hrsACE2 
Different concentrations of hrsACE2 were mixed with 106 particles of SARS-CoV-2 for 30min at 
37°C in a final volume of 50µl per well in STemPro 34 complete medium (blood-vessels) or 
advanced RPMI medium (Kidneys) as described above. Organoids were then infected with the 
mixes for 1 hour at 37°C, washed 3 times with PBS and 100µl per well of new medium was added. 
To detect intracellular viral RNA, organoids were washed 3 times with PBS, pooled (5 
organoids/condition for blood-vessels; 3 organoids/condition for kidneys) and lysed using 
Trizol™ (Thermofisher) before analysis by qRT-PCR for viral RNA detection.  
 
Cytotoxicity assay 
To determine whether human or mouse rsACE2 are toxic to cells, 104 Vero E6 cells per well were 
seeded in a 96-well plate. 24h post-seeding, 25µl of different concentrations (25 – 200g/ml of 
rsACE2 were added in triplicate and incubated for 15h. 15h post-treatment, cytotoxicity was 
determined using the CellTiter-Glo® Luminescent cell viability assay (Promega) following the 
following the manufacturer's protocol using 50µl of CellTiter-Glo® Reagent per well. 
 
qRT-PCR 
Samples were extracted using Direct-zol RNA MiniPrep kit (Zymo Research). qRT-PCR was 
performed using E-gene SARS-CoV-2 primers/probe following guidelines by the World Health 
Organization (https://www.who.int/docs/default-source/coronaviruse/wuhan-virus-assay-
v1991527e5122341d99287a1b17c111902.pdf)  
Forward primer: 5´-ACAGGTACGTTAATAGTTAATAGCGT-3’  
Reverse primer: 5´-ATATTGCAGCAGTACGCACACA-3’ 
Probe: FAM-ACACTAGCCATCCTTACTGCGCTTCG-QSY  
RNase P was used as an endogenous gene control to normalize the levels of intracellular viral 
RNA. 
Forward primer: AGATTTGGACCTGCGAGCG  
Reverse primer GAGCGGCTGTCTCCACAAGT  
probe: FAM-TTCTGACCTGAAGGCTCTGCGCG-MGB 
Primers used for tubular markers in kidney organoids are listed in Supplementary Table 1. 
 
Single cell sequencing of kidney organoids 
Kidney organoids were homogenized using 21G and 26 1/2G syringes and further dissociated 
using Accumax (07921, Stem Cell Technologies9 for 15 min at 37ºC followed by Trypsin-EDTA 
0,25% (wt/vol) trypsin (25300-054, Life Technologies) for additional 15 min at 37ºC. The reaction 
was deactivated by adding 10% FBS. The solution was then passed through a 40 m cell strainer 
and frozen in Advanced RPMI 1640 basal medium (ThermoFisher) in the presence of DMSO10%. 
Cells were thawed and centrifuged at 1,500 RPM for 5 minutes, stained with sytox blue 
(Thermofisher) and sorted by FACS to remove the nonviable cells, generating a single cell 
suspension with greater than 90% viability analyzed using the cellometer K2 (Nexcelom 
Biocience). Libraries were prepared using the Chromium Single Cell 3ʹ GEM, v3, (PN-1000075, 
10X genomics) following the manufacturer´s instructions and sequenced with a NEXTseq500 
(R1:28, R2: 55, i7:8) up to 30.000 reads per cell.  
 
Histological analysis 
Kidneys organoid and LTL+ cells were washed with PBS. Next samples were fixed with 4% 
paraformaldehyde (153799, Aname) for 20 min at room temperature. Specimens were washed 
twice with PBS and further blocked using Tris-buffered saline (TBS) with 6% donkey serum (S30, 
Millipore) and 1% Triton X-100 (T8787, Sigma) for 1h at room temperature. After three rinses 
with antibody dilution buffer, samples were treated for 4h at room temperature with fluorescent 
conjugated secondary antibodies (Alexa Fluor (A) Cy3- or A647-; 1:200). A previous blocking 
step with a streptavidin/biotin blocking kit (SP-2002, Vector Labs) was performed for biotinylated 
LTL (B-1325, Vector Labs) and Alexa Fluor 488-conjugated streptavidin (SA5488, VectorLabs) 
to detect LTL+ cells. Antibodies to NEPHRIN (R&D SYSTEMS 4269; 1:100) and LAMININ 
(Sigma L9393; 1:50), SGLT2 (Abcam AB37296; 1:100), NaKATPase (Abcam; AB209299; 
1:200) and SLC3A1 (Sigma HPA038360; 1:50) were used overnight at 4°C diluted in antibody 
dilution buffer consisting of TBS with 6% donkey serum and 0.5% Triton X-100. Nuclei were 
detected using 4,6-diamidino-2-phenylindole (DAPI; 1:5000, D1306, Life Technologies) for 
30min. For mounting, samples were immersed in Fluoromount-G (0100-01, Southern Biotech). 
Sample confocal images were acquired with an SP5 Leica microscope and LTL + were analysed 
using Image J. 
 
Flow cytometry 
For the isolation of LTL+ cells kidney organoids were stained with fluorescein-conjugated LTL 
(FL-1321, Vector Laboratories). Then specimens were dissociated to single cells using Accumax 
(07921, Stem Cell Technologies) for 15min followed by 0.25% (wt/vol) trypsin (25300–054, Life 
Technologies) for 15min at 37 °C. For LTL+ cells isolation FACSDiva software version 8.0.1 (BD 
Biosciences) was used in the FACS Aria Fusion instrument (BD Biosciences). 
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
 
Kidney Organoid scRNA-seq Data Analysis 
Libraries were pre-processed using Cell Ranger (3.0.1) from 10X Genomics. The computational 
analysis was performed using Seurat (3.0.2) (Stuart et al., 2019). Initial quality control parameters 
were defined based on the distributions of the number of detected genes per cell, the number of 
UMIs per cell and the % of UMIs assigned to mitochondrial genes. The selected thresholds were: 
668 < UMIs per cell < 23101, 489 < Genes per cell < 5651 and % UMIs assigned to mitochondrial 
genes < 50. The dataset was subjected to normalization, identification of highly variable features 
and scaling using the SCTransform function of the Seurat package. Principal component analysis 
was performed, and 20 components were kept for further analysis. Clustering was performed by 
setting the resolution parameter to 0.4. Dimensional reduction was done using the RunUMAP 
function of the Seurat R package. Cell markers were identified by using a Wilcoxon test. Genes 
with adjusted p.value < 0.5 were retained. Clusters were labelled by comparing the expression of 
the identified markers with publicly available databases (Wu et al., 2018b) located in KIT (Kidney 
Interactive Transcriptomics webpage (http://humphreyslab.com/SingleCell/).  
 
Statistics.  
Statistical analyses were conducted using GraphPad Prism 8 (GraphPad) and significance was 
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